Merus N.V. (NASDAQ:MRUS - Get Free Report) COO Peter B. Silverman sold 34,000 shares of the company's stock in a transaction on Friday, June 20th. The stock was sold at an average price of $52.76, for a total value of $1,793,840.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Merus Stock Performance
Shares of NASDAQ MRUS traded up $1.39 during mid-day trading on Tuesday, hitting $54.13. The stock had a trading volume of 644,395 shares, compared to its average volume of 755,859. The firm has a market cap of $3.75 billion, a PE ratio of -13.27 and a beta of 1.04. The company has a 50 day moving average of $48.03 and a two-hundred day moving average of $44.60. Merus N.V. has a twelve month low of $33.19 and a twelve month high of $62.98.
Merus (NASDAQ:MRUS - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($1.40) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.23). Merus had a negative net margin of 506.73% and a negative return on equity of 35.99%. The firm had revenue of $26.49 million during the quarter, compared to analyst estimates of $7.82 million. Equities research analysts predict that Merus N.V. will post -3.85 EPS for the current fiscal year.
Institutional Investors Weigh In On Merus
Large investors have recently bought and sold shares of the company. FMR LLC raised its position in Merus by 0.4% during the 4th quarter. FMR LLC now owns 6,899,521 shares of the biotechnology company's stock worth $290,125,000 after buying an additional 25,595 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of Merus by 34.9% in the first quarter. Wellington Management Group LLP now owns 4,718,172 shares of the biotechnology company's stock worth $198,588,000 after acquiring an additional 1,220,519 shares during the period. Paradigm Biocapital Advisors LP raised its holdings in shares of Merus by 99.4% during the first quarter. Paradigm Biocapital Advisors LP now owns 3,369,699 shares of the biotechnology company's stock worth $141,831,000 after purchasing an additional 1,679,777 shares during the last quarter. Avoro Capital Advisors LLC raised its holdings in shares of Merus by 56.8% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,125,000 shares of the biotechnology company's stock worth $89,356,000 after purchasing an additional 770,000 shares during the last quarter. Finally, Boxer Capital Management LLC acquired a new position in Merus during the fourth quarter valued at $79,895,000. Hedge funds and other institutional investors own 96.14% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on the company. Bank of America decreased their price objective on Merus from $73.00 to $70.00 and set a "buy" rating for the company in a research note on Monday, March 10th. BMO Capital Markets set a $110.00 price target on shares of Merus and gave the company an "outperform" rating in a research report on Friday, May 23rd. William Blair restated an "outperform" rating on shares of Merus in a report on Monday, April 28th. HC Wainwright reaffirmed a "buy" rating and issued a $85.00 price objective on shares of Merus in a research report on Monday, March 3rd. Finally, Needham & Company LLC reissued a "buy" rating and set a $75.00 target price on shares of Merus in a research report on Monday, May 19th. Twelve research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $84.64.
Check Out Our Latest Stock Analysis on MRUS
About Merus
(
Get Free Report)
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Merus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.
While Merus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
